You are here: Industry Insights > I-Mab

News List

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting prnasia
November 10, 2020
I-Mab announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab (also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma.
MorphoSys, I-Mab Announce IND Application Clearance for Advanced Cancer Treatment americanpharmaceuticalreview
September 27, 2020
MorphoSys and I-Mab jointly announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer prnasia
September 18, 2020
MorphoSys AG and I-Mab jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance contractpharma
September 07, 2020
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million prnasia
July 16, 2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repurchase program under
I-Mab Release Results for Anti-GM-CSF Antibody TJM2 to Treat CRS-Related COVID-19 americanpharmaceuticalreview
June 03, 2020
I-Mab announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study of TJM2 in patients with cytokine release syndrome (CRS) associated with severe coronavirus disease 2019 (COVID-19).
I-Mab Announces IND Clearance to Treat COVID-19 Cytokine Release Syndrome americanpharmaceuticalreview
April 09, 2020
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2.
I-Mab, Kalbe Genexine Enter Strategic Pact contractpharma
April 01, 2020
KG Bio will have option for exclusive rights to commercialize two I-Mab product candidates.
I-Mab Appoints BD SVP contractpharma
March 30, 2020
Fernando J. Sallés will be responsible for leading global out-licensing efforts and co-development partnerships/strategic alliances.
I-Mab Makes Executive Appointment contractpharma
March 25, 2020
Names Gigi Feng as vice president and global head of corporate communications.

Previous page 1 2 3 4 5 6 Next page